Cobbold S, Martin G, Waldmann H
Transplantation. 1986 Sep;42(3):239-47. doi: 10.1097/00007890-198609000-00003.
One of the major complications of allogeneic bone marrow transplantation is graft-versus-host disease. This can be avoided by removing the mature T cells from the marrow, most conveniently by the use of monoclonal antibodies. However, T cell purging results in an increased tendency for the recipient to reject the donor marrow. We have developed monoclonal antibodies to L3/T4 and Lyt-2 that specifically deplete functional T cell subsets in mice. We demonstrate that such reagents can be used to control both graft-versus-host disease and marrow rejection in mouse models of bone marrow transplantation across one-haplotype or two-haplotype major histocompatibility differences. Such strategies to abrogate host resistance, by administration of anti-T-cell monoclonal antibodies to the recipient, may complement marrow T cell purging for human allogeneic bone marrow transplantation.
同种异体骨髓移植的主要并发症之一是移植物抗宿主病。通过从骨髓中去除成熟T细胞可以避免这种情况，最方便的方法是使用单克隆抗体。然而，T细胞清除会增加受体排斥供体骨髓的倾向。我们已经开发出针对L3/T4和Lyt-2的单克隆抗体，它们能特异性地清除小鼠体内的功能性T细胞亚群。我们证明，在跨越一个单倍型或两个单倍型主要组织相容性差异的骨髓移植小鼠模型中，此类试剂可用于控制移植物抗宿主病和骨髓排斥反应。通过给受体注射抗T细胞单克隆抗体来消除宿主抗性的此类策略，可能会补充人类同种异体骨髓移植中的骨髓T细胞清除。
